The US HHS has launched a $500m initiative to accelerate the development of universal vaccines targeting viruses with ...

Data from the NERO study investigating Zejula in mesothelioma was presented at the American Association of Cancer Research ...

4D Molecular Therapeutics (4DMT) has received regenerative medicine advanced therapy (RMAT) designation from the US Food and ...

As scientists explore treating genetic disorders before birth, the promise of foetal gene therapy is growing—but there are ...

Whilst 2025 outlooks include cost impact from existing tariffs, companies have not adjusted their guidance for future ...

The UK MHRA has granted marketing authorisation to Bavarian Nordic's Vimkunya vaccine for preventing the chikungunya virus.

Repare Therapeutics has entered into an out-licensing agreement with Canadian biotechnology firm DCx for discovery platforms ...

While the pharmaceutical industry is currently exempt from US tariffs, there is an increased risk to the stability of the ...

Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.

The London Cancer Hub has been identified as a key district for ‘frontier innovation’ by London Mayor Sadiq Khan.

Companies are developing myostatin inhibitors for GLP-1RA-related muscle loss, but some experts question their necessity.

Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.